Literature DB >> 19484145

Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer.

Kevin M Hart1, S Peter Bak, Anselmo Alonso, Brent Berwin.   

Abstract

Ovarian tumor progression is marked by the peritoneal accumulation of leukocytes. Among these leukocytes, an immunosuppressive CD11b(+)CD11c(+) population has been identified in both human and ovarian tumors. The use of transplantable models of murine ovarian tumors has demonstrated that this population promotes ovarian tumor growth, whereas elimination of this population has been shown to inhibit ovarian tumor progression. Despite the demonstrated importance of these cells to ovarian tumor progression, the mechanisms by which these cells are recruited to the peritoneal tumor are largely unknown. Therefore, this study analyzes the mechanisms these cells use to migrate to the peritoneum with the goal of therapeutically blocking their recruitment and subsequent immunosuppressive activity. Recent studies have identified that CX(3)CR1, Gr-1, and CCR2 delineate phenotypic and functional murine monocyte subsets. Here, we report that CX(3)CR1(lo)Gr-1(hi) cells dominate the population of peritoneal CD11b(+) leukocytes early in murine tumor development; however, the CX(3)CR1(hi) population of cells present in the peritoneum dramatically increases in both total numbers and percentage during tumor progression. Functional analyses reveal that both of these CX(3)CR1 subsets are immunosuppressive to naive CD8(+) and CD4(+) T-cell responses. Importantly, we demonstrate that CCR2 is a critical functional facilitator of leukocyte recruitment to the ovarian tumor microenvironment, and its genetic deletion results in a reduced tumor burden compared with wild-type mice. These results demonstrate that subsets of immunosuppressive leukocytes are recruited to the ovarian tumor environment through the CCR2 pathway, which offers a viable therapeutic target to inhibit their migration to the tumor site.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484145      PMCID: PMC2685445          DOI: 10.1593/neo.09228

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  48 in total

1.  The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK.

Authors:  Simone R Green; Ki Hoon Han; Yiming Chen; Felicidad Almazan; Israel F Charo; Yury I Miller; Oswald Quehenberger
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.

Authors:  Bo Huang; Zhang Lei; Jie Zhao; Wei Gong; Jinwen Liu; Zhenyong Chen; Yi Liu; Dong Li; Ye Yuan; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Cancer Lett       Date:  2007-01-25       Impact factor: 8.679

Review 3.  Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.

Authors:  Vincenzo Bronte; Sara Cingarlini; Ilaria Marigo; Carmela De Santo; Giovanna Gallina; Luigi Dolcetti; Stefano Ugel; Elisa Peranzoni; Susanna Mandruzzato; Paola Zanovello
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

Review 4.  Migratory fate and differentiation of blood monocyte subsets.

Authors:  Frank Tacke; Gwendalyn J Randolph
Journal:  Immunobiology       Date:  2006-07-10       Impact factor: 3.144

5.  Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.

Authors:  Sofia Halin; Stina Häggström Rudolfsson; Nico Van Rooijen; Anders Bergh
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

6.  Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice.

Authors:  Toni M Robinson-Smith; Idit Isaacsohn; Carol A Mercer; Mingfu Zhou; Nico Van Rooijen; Nader Husseinzadeh; Molly M McFarland-Mancini; Angela F Drew
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.

Authors:  S Peter Bak; Julie Jo Walters; Motohiro Takeya; Jose R Conejo-Garcia; Brent L Berwin
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

8.  Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior.

Authors:  Cedric Auffray; Darin Fogg; Meriem Garfa; Gaelle Elain; Olivier Join-Lambert; Samer Kayal; Sabine Sarnacki; Ana Cumano; Gregoire Lauvau; Frederic Geissmann
Journal:  Science       Date:  2007-08-03       Impact factor: 47.728

9.  Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Authors:  Thorsten Hagemann; Stephen C Robinson; Richard G Thompson; Kellie Charles; Hagen Kulbe; Frances R Balkwill
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

10.  Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis.

Authors:  Ludovic Arnold; Adeline Henry; Françoise Poron; Yasmine Baba-Amer; Nico van Rooijen; Anne Plonquet; Romain K Gherardi; Bénédicte Chazaud
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  27 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.

Authors:  Ayse Bassez; Hanne Vos; Laurien Van Dyck; Giuseppe Floris; Ingrid Arijs; Christine Desmedt; Bram Boeckx; Marlies Vanden Bempt; Ines Nevelsteen; Kathleen Lambein; Kevin Punie; Patrick Neven; Abhishek D Garg; Hans Wildiers; Junbin Qian; Ann Smeets; Diether Lambrechts
Journal:  Nat Med       Date:  2021-05-06       Impact factor: 53.440

5.  Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver.

Authors:  James G Cripps; Jing Wang; Ann Maria; Ian Blumenthal; James D Gorham
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

Review 6.  Plasticity of myeloid-derived suppressor cells in cancer.

Authors:  Evgenii Tcyganov; Jerome Mastio; Eric Chen; Dmitry I Gabrilovich
Journal:  Curr Opin Immunol       Date:  2018-03-14       Impact factor: 7.486

7.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

8.  Ovarian tumor-induced T cell suppression is alleviated by vascular leukocyte depletion.

Authors:  S Peter; G Bak; Kevin Hart; Brent Berwin
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

Review 9.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

10.  Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.

Authors:  Paul Spear; Amorette Barber; Agnieszka Rynda-Apple; Charles L Sentman
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.